Cellectis Publishes Study on a New Gene Insertion Method
Cellectis announces the publication of an article in Nature Communications on the use of single-stranded circular DNA for gene insertion in hematopoietic stem cells.
Enhanced Efficiency with Circular DNA
According to Cellectis' press release, the company has demonstrated that single-stranded circular DNA (CssDNA) is an effective template for gene insertion in hematopoietic stem and progenitor cells (HSPCs). The results show that this approach achieves an efficiency 3 to 5 times higher than methods using linear single-stranded DNA (LssDNA), with an insertion rate exceeding 40%. In comparison, traditional viral vectors like AAV6 raise safety and efficiency concerns, making the CssDNA method particularly noteworthy.
Broad Applications and Precision
The company states that this breakthrough in the use of CssDNA allows for the precise insertion of entire genes into subpopulations of HSPCs of therapeutic interest, and can also be applied to other cell types, such as primary T cells. This non-viral strategy is presented as a promising alternative to current viral methods, expanding the possibilities for gene therapy treatments.
Ongoing Development and Future Prospects
Cellectis, headquartered in Paris with offices in New York and Raleigh, continues to develop cellular and gene therapies using its TALEN technology. According to Julien Valton, Vice-President of Gene Therapy at Cellectis, this non-viral method represents a step forward towards the next generation of therapies. As a company listed on Euronext Growth and Nasdaq, Cellectis aims to become a leader in the field of allogeneic immunotherapies with its CAR-T cell-based products.
